The
Company excluded the following from the computation of diluted net loss per share attributable to common shareholders for the three months
ended March 31, 2026 and 2025 because including them would have had an anti-dilutive effect:
SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE
| | |
For the Three Months Ended | | |
For the Three Months Ended | |
| | |
March 31, | | |
March 31, | |
| | |
2026 | | |
2025 | |
| Stock options to purchase common stock outstanding | |
| 1,352,279 | | |
| 1,352,279 | |
| Warrants to purchase common stock outstanding | |
| 350,000 | | |
| 350,000 | |
| Total | |
| 1,702,279 | | |
| 1,702,279 | |
| Anti-dilutive shares | |
| 1,702,279 | | |
| 1,702,279 | |
|